Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102113 · ClinicalTrials.gov registry record · Early Phase 1
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
A Early Phase 1 study of Schizophrenia and Cannabis Use, sponsored by Yale University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02102113: Active Early Phase 1 study of Schizophrenia and Cannabis Use, sponsored by Yale University.
NCT02102113 is a Early Phase 1 study of Schizophrenia and Cannabis Use that is active but no longer recruiting, run by Yale University. The registered enrollment target is 21 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02102113, a Early Phase 1 study of Schizophrenia and Cannabis Use, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Primary Outcome
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Very Low Dose THC
- DRUG Low Dose THC
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-01 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What the registry record for NCT02102113 still lists
NCT02102113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02102113 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02102113 about?
NCT02102113 is a clinical study titled "Probing the Cannabinoid System in Individuals With a Family History of Psychosis". The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a ...
What is the current status of trial NCT02102113?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2014-01. Estimated completion is 2026-12.
What conditions does trial NCT02102113 study?
This clinical trial studies the following conditions: Schizophrenia, Cannabis Use, Psychosis, THC, Marijuana.
What interventions are being tested in trial NCT02102113?
The interventions under investigation include: Placebo (DRUG), Very Low Dose THC (DRUG), Low Dose THC (DRUG).
Who is sponsoring clinical trial NCT02102113?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02102113 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02102113's enrollment target sits among peer trials
21 282nd of 315 higher than 31 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia